← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 227개
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
CGTBiologicstaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib Hydrochloride (Defactinib Hydrochloride)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 3상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

CAR-T infusion (CAR-T infusion)

Refractory Metastatic Colorectal Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 67%임상시험 2상태 ACTIVE
CGTBiologicstaleGyala TherapeuticsPhase 1

CD84-CART (CD84-CART)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleCartesian TherapeuticsPhase 2

CAR-T (Chimeric Antigen Receptor T Cells, Chimeric Antigen Receptor T Cells (CAR-T))

Relapsed or Refractory Aggressive B-cell Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 67%임상시험 2상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
ADCBiologicstaleMenarini GroupPhase 1

MEN1309 (MEN1309)

Metastatic Solid Tumors; Relapsed/Refractory Non-Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 2상태 DISCONTINUED
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
AntibodystaleBeiGenePhase 3

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
효능 ORR 100%임상시험 2상태 DISCONTINUED
CGTBiologicstaleNektar TherapeuticsPhase 1

Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Polymer-conjugated IL-15 Receptor Agonist NKTR-255)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
AntibodystalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 89%임상시험 2상태 DISCONTINUED
CGTBiologicstaleCancer Research UKPhase 1

1RG-CART (1RG-CART)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Abemaciclib, dexamethasone, ixazomib, pomalidomide (Abemaciclib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

5 / 12 페이지

← 이전다음 →